215 related articles for article (PubMed ID: 33782280)
1. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.
Fathpour G; Jafari E; Hashemi A; Dadgar H; Shahriari M; Zareifar S; Jenabzade AR; Vali R; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2021 Jul; 46(7):540-548. PubMed ID: 33782280
[TBL] [Abstract][Full Text] [Related]
2. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ
J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M
Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757
[TBL] [Abstract][Full Text] [Related]
4.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
5. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
8. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
9. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma.
Gains JE; Bomanji JB; Fersht NL; Sullivan T; D'Souza D; Sullivan KP; Aldridge M; Waddington W; Gaze MN
J Nucl Med; 2011 Jul; 52(7):1041-7. PubMed ID: 21680680
[TBL] [Abstract][Full Text] [Related]
10. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
Basu S; Ranade R; Thapa P
World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
14. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
[TBL] [Abstract][Full Text] [Related]
16. Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.
Alexander N; Vali R; Ahmadzadehfar H; Shammas A; Baruchel S
Curr Radiopharm; 2018; 11(1):14-21. PubMed ID: 29243585
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of peptide receptor radionuclide therapy with
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
[No Abstract] [Full Text] [Related]
18. Peptide Receptor Radionuclide Therapy Using
Kalantarhormozi M; Hassanzadeh S; Rekabpour SJ; Ravanbod MR; Jafari E; Amini A; Dadgar H; Mahmoudpour M; Nabipour I; Jokar N; Assadi M
World J Nucl Med; 2022 Sep; 21(3):215-221. PubMed ID: 36060085
[No Abstract] [Full Text] [Related]
19. Initial clinical evaluation of indigenous
Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
[No Abstract] [Full Text] [Related]
20. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S
ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
